Nuwellis (NUWE) Projected to Post Earnings on Tuesday

Nuwellis (NASDAQ:NUWE) is projected to release its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Nuwellis to post earnings of ($1.00) per share and revenue of $2.0940 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 9:00 AM ET.

Nuwellis (NASDAQ:NUWE) last issued its earnings results on Tuesday, March 10th. The company reported ($1.50) EPS for the quarter, beating the consensus estimate of ($1.56) by $0.06. The company had revenue of $2.42 million during the quarter, compared to the consensus estimate of $2.31 million. Nuwellis had a negative return on equity of 6,094.26% and a negative net margin of 211.86%.

Nuwellis Price Performance

Shares of NUWE traded down $0.02 during trading hours on Tuesday, hitting $1.10. The stock had a trading volume of 16,201 shares, compared to its average volume of 1,558,815. The firm has a 50 day simple moving average of $1.24 and a 200-day simple moving average of $2.06. The firm has a market capitalization of $2.70 million, a P/E ratio of -0.01 and a beta of 0.25. Nuwellis has a 1-year low of $0.96 and a 1-year high of $43.26.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Nuwellis in a research note on Friday, March 27th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

Nuwellis Company Profile

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.